Decisions not to treat patients may, of course, be appropriate in the context of palliative management, patient choice, or where there is an increased cancer-related risk of adverse drug effects (such as bleeding with antiplatelet therapies, hypotension, or renal dysfunction with ACE inhibitor/angiotensin receptor blocker).32 Here, ACE is linked to cancer.